N-[2-(2-Methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a Bisnitroimidazole with Enhanced Selectivity as a Bioreductive Drug

Cancer Research

Volumn 55, Issue 3, 1995, Pages 574-580

  Moselen, John W ^a   Hay, Michael P ^a   Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; CHLORAMBUCIL; DOUBLE STRANDED DNA; METRONIDAZOLE; MISONIDAZOLE; N [2 (1 IMIDAZOLYL)ETHYL] 4 (2 NITRO 1 IMIDAZOLYL)BUTANAMIDE; N [2 (2 METHYL 5 NITRO 1 IMIDAZOLYL)ETHYL] 4 (2 NITRO 1 IMIDAZOLYL)BUTANAMIDE; NITROIMIDAZOLE DERIVATIVE; NSC 639862; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL HYPOXIA; CELL KILLING; CHO CELL; CONTROLLED STUDY; DNA CROSS LINKING; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

AEROBIOSIS; ANIMAL; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; CRICETULUS; HAMSTERS; MAMMARY NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; OXIDATION-REDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0028952450     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Chapman, J. D. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother. Oncol., 20 (Suppl.): 13–19, 1991.
2. Henk, J. M., and Smith, C. W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Lancet, 2: 104–105, 1977.
3. Bush, R. S., Jenkin, R. D. T., Allt, W. E. C., Beale, F. A., Bean, H., Dembo, A. J., and Pringle, J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer, 37: 302–306, 1978.
4. Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., and Hartz, W. H. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 14: 831–838, 1988.
5. Overgaard, J. Importance of tumour hypoxia in radiotherapy: a meta-analysis of controlled clinical trials. Radiother. Oncol., 24: S64, 1992.
6. Hockel, M., Knoop, C., Schlenger, K., Voradran, B., Baubmann, E., Mitze, M., Knapstein, P. G., and Vaupel, P. Intratumoral p02 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol., 26: 45–50, 1993.
7. McNally, N. J., Denekamp, J., Sheldon, P., Flockhart, I. R., and Stewart, F. A. Radiosensitization by misonidazole (Ro 07–0582). The importance of timing and tumor concentration of sensitizer. Radiat. Res., 73: 568–580, 1978.
8. Denekamp, J., Hirst, D. G., Stewart, F. A., and Terry, N. H. A. Is tumour radiosensitization by misonidazole a general phenomen? Br. J. Cancer, 41: 1–9, 1980.
9. Hall, E. J., and Roizin-Towle, L. Hypoxic sensitizers: radiobiological studies at the cellular level. Radiology, 117: 453–457, 1975.
10. Mohindra, J. K., and Rauth, A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res., 36: 930–936, 1976.
11. Moore, B. A., Palcic, B., and Skarsgard, L. D. Radiosensitizing and toxic effects of the 2-nitroimidazole Ro-07–0582 in hypoxic mammalian cells. Radiat. Res., 67: 459–473, 1976.
12. Brown, J. M., and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50: 7745–7749, 1990.
13. Adams, G. E. Redox, radiation, and reductive bioactivation. Radiat. Res., 132: 129–139, 1992.
14. Wilson, W. R. Tumour hypoxia: challenges for cancer chemotherapy. In: M.J. Waring and B. A. J. Ponder (eds.), Cancer Biology and Medicine, Vol. 3, pp. 87–131. Lancaster, United Kingdom: Kluwer Academic Publishers, 1992.
15. Brown, J. M., and Koong, A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl. Cancer. Inst., 83: 178–185, 1991.
16. Denny, W. A., and Wilson, W. R. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev., 12: 135–151, 1993.
17. Brown, J. M., and Giaccia, A. J. Tumour hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol., 65: 95–102, 1994.
18. Chapman, J. D., Franko, A. J., and Sharplin, J. A marker for hypoxic cells in tumours with potential clinical applicability. Br. J. Cancer, 43: 546–550, 1981.
19. Hodgkiss, R. J., Jones, G., Long, A., Parrick, J., Smith, K. A., Stratford, M. R. L., and Wilson, G. D. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br. J. Cancer, 63: 119–125, 1991.
20. Raleigh, J. A., Miller, G. G., Franko, A. J., Koch, C. J., Fuciarelli, A. F., and Kelly, D. A. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br. J. Cancer, 56: 395–396, 1987.
21. Koh, W-J., Rasey, J. S., Evans, M. L., Grierson, J. R., Lewellen, T. K., Graham, M. M., Krohn, K. A., and Griffin, T. W. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys., 22: 199–212, 1991.
22. Rauth, A. M., Paciga, J. E., and Mohindra, J. K. In vivo studies of the cytotoxicity of hypoxic cell radiosensitizers. In: L. W. Brady (ed.), Radiation Sensitizers: Their Use in the Clinical Management of Cancer, pp. 207–214. New York: Masson Publishing, 1980.
23. Adams, G. E., Ahmed, I., Sheldon, P. W., and Stratford, I. J. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br. J. Cancer, 49: 571–577, 1984.
24. Stratford, I. J., O′Neill, P., Sheldon, P. W., Silver, A. R. J., Walling, J. M., and Adams, G. E. RSU 1069, a nitroimidazole compound containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem. Pharmacol., 35: 105–109, 1986.
25. Chaplin, D. J., Durand, R. E., Stratford, I. J., and Jenkins, T. C. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int. J. Radiat. Oncol. Biol. Phys., 12: 1091–1095, 1986.
26. Hill, R. P., Gulyas, S., and Whitmore, G. F. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br. J. Cancer, 53: 743–751, 1986.
27. Cole, S., Stratford, I. J., Fielden, E. M., Adams, G. E., Leopold, W., Elliott, W., Suto, M., and Sebolt-Leopold, J. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908). Int. J. Radiat. Oncol. Biol. Phys., 22: 545–548, 1992.
28. Stratford, I. J., Walling, J. M., and Silver, A. R. J. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br. J. Cancer, 53: 339–344, 1986.
29. Whitmore, G. F., and Gulyas, S. Studies on the toxicity of RSU-1069. Int. J. Radiat. Oncol. Biol. Phys., 12: 1219–1222, 1986.
30. O′Neill, P., McNeill, S. S., and Jenkins, T. C. Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131. Biochem. Pharmacol., 36: 1787–1792, 1987.
31. Ahmed, I., Jenkins, T. C., Walling, J. M., Stratford, I. J., Sheldon, P. W., Adams, G. E., and Fielden, E. M. Analogues of RSU-1069: Radiosensitization and toxicity in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 12: 1079–1081, 1986.
32. Wilson, W. R., van Zijl, P., and Denny, W. A. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine W-oxide. Int. J. Radiat. Oncol. Biol. Phys., 22: 693–696, 1992.
33. Hay, M. P., Wilson, W. R., Moselen, J. W., Palmer, B. D., and Denny, W. A. Hypoxia-selective antitumour agents. 8. Bis-(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J. Med. Chem., 37: 381–391, 1994.
34. Jenkins, T. C., Naylor, M. A., O′Neill, P., Threadgul, M. D., Cole, S., Stratford, I. J., Adams, G. E., Fielden, M., Suto, M. J., and Stier, M. A. Synthesis and evaluation of a[[(2-haloethyl)amino]methyl]-2-nitro-lN-imidazole-l-ethanols as prodrugs of a-[(l-aziridinyl)methyl]-2-nitro-lfN-imidazole-l-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem., 33: 2603–2610, 1990.
35. Thompson, L. H., Fong, S., and Brookman, K. Validation of conditions for efficient detection of HPRT and APRT mutations in suspension-cultured Chinese hamster ovary cells. Mutat. Res., 74: 21–36, 1980.
36. Thompson, L. H., Rubin, J. S., Cleaver, J. E., Whitmore, G. F., and Brookman, K. A screening method for isolating DNA repair-deficient mutants of CHO cells. Somatic Cell Genet., 6: 391–405, 1980.
37. Sum, B. G., Atwell, G. J., and Wilson, W. R. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br. J. Cancer, 70: 596–603, 1994.
38. Koch, C. J. Polarographie oxygen sensor. U. S. Patent 5030036, 1991.
39. Kohn, K. W., Ewigra, G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: E. Friedberg and P. Hanawalt (eds.), DNA Repair. A Laboratory Manual of Research Procedures, pp. 379–401. New York: Marcel Dekker, Inc., 1981.
40. Bradley, M. O., and Kohn, K. W. X-ray induced DNA double strand break production and repair in mammalian cells as measured by neutral filter elution. Nucleic Acids Res., 7: 793–804, 1979.
41. Silobrcic, V., and Suit, H. D. Tumor-specific antigen(s) in a spontaneous mammary carcinoma of C3H mice. I. Quantitative cell transplants into mammary-tumor-agent-positive and-free mice. J. Natl. Cancer Inst., 39: 1113–1119, 1967.
42. Hoy, C. A., Salazar, E. P., and Thompson, L. H. Rapid detection of DNA-damaging agents using repair-deficient CHO cells. Mutat. Res., 130: 321–332, 1984.
43. Hoy, C. A., Thompson, L. H., Mooney, C. L., and Salazar, E. P. Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to afunctional alkylating agents. Cancer Res., 45: 1737–1743, 1985.
44. Rauth, A. M., McClelland, R. A., Michaels, H. B., and Battistella, R. The oxygen dependence of the reduction of nitroimidazoles in a radiolytic model system. Int. J. Radiat. Oncol. Biol. Phys., 10: 1323–1326, 1984.
45. Whitmore, G. F., Dulhanty, A., Varghese, A. J., and Gulyas, S. Response of repair and reduction deficient mutants to agents requiring bioreduction. In: G. E. Adams et al. (eds.), Selective Activation of Drugs by Redox Processes, pp. 285–294. New York: Plenum Publishing Corp., 1990.
46. Wilson, W. R., Moselen, J. W., Hay, M. P., and Denny, W. A. Bis-nitroimidazole bioreductive drugs: evidence for in situ reduction of DNA-bound metabolites. Abstract P35–588. In: Forty-second Annual Meeting, Radiation Research Society, 1994.
47. Ward, J. F. Symposium on Radical Processes in Radiobiology and Carcinogenesis. Radiat. Res., 86: 185–195, 1981.
48. Ward, J. F. Biochemistry of DNA lesions. Radiat. Res., 104: S103-S111, 1985.
49. Dedon, P. C., and Goldberg, I. H. Free radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin and calicheamicin. Chem. Res. Toxicol., 5: 311–332, 1992.
50. Zein, N., McGahren, W. J., Morton, G. O., Ashcroft, J., and Ellestad, G. A. Exclusive abstraction of non-exchangeable hydrogens from DNA by calicheamicin yl1. J. Am. Chem. Soc., III: 6888–6890, 1989.
51. Meschwitz, S. M., and Goldberg, I. H. Selective abstraction of 2H from C5′ of thymidylate in oligodeoxynucleotide by radical center at C6 of diradical species of neocarzinostatin: chemical evidence for structure of activated drug-DNA complex. Proc. Natl. Acad. Sci. USA, 88: 3047–3051, 1991.
52. Hatayama, T., and Goldberg, I. H. DNA damage and repair in relation to cell killing in neocarzinostatin-treated HeLa cells. Biochim. Biophys. Acta, 563: 59–71, 1979.
53. Shiloh, Y., van der Schans, G. P., Lohman, P. H. M., and Becker, Y. Induction and repair of DNA damage in normal and ataxia telangiectasia skin fibroblasts treated with neocarzinostatin. Carcinogenesis (Lond.), 4: 917–921, 1983.
54. Palmer, B. D., Wilson, W. R., Cliffe, S., and Denny, W. A. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J. Med. Chem., 35: 3214–3222, 1992.
55. Varghese, A. J., and Whitmore, G. F. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res., 40: 2165–2169, 1980.
56. Miller, G. G., Ngan-Lee, J., and Chapman, J. D. Intracellular localization of radio-actively labeled misonidazole in EMT-6 tumour cells in vitro. Int. J. Radiat. Oncol. Biol. Phys., 8: 741–744, 1982.
57. Malliaros, D. P., and Goldman, P. Interaction of metronidazole with Escherichia coli deoxyribonucleic acid. Biochem. Pharmacol., 42: 1739–1744, 1991.
58. Palcic, B., and Skarsgard, L. D. Cytotoxicity of misonidazole and DNA damage in hypoxic mammalian cells. Br. J. Cancer, 37: 54–59, 1978.
59. Murray, D., and Meyn, R. E. DNA damage in normal and neoplastic mouse tissues after treatment with misonidazole in vivo. Biochem. Pharmacol., 34: 3275–3279, 1985.
60. Olive, P. L. Mechanisms of the in vitro toxicity of nitroheterocycles including Flagyl and misonidazole. In: L. W. Brady (ed.), Radiation Sensitizers. Their Use in the Clinical Management of Cancer, pp. 39–44. New York: Masson Publishing, 1980.
61. Lafleur, M. V. M., Zahoor, A., Knight, R. C., Pluijmackers-Westmijze, E. J., Loman, H., and Edwards, D. I. Electrolytic reduction of nitroheterocyclic drugs leads to biologically important damage in DNA. Int. J. Radiat. Biol., 48: 917–925, 1985.
62. Berube, L. R., Farah, S., McClelland, R. A., and Rauth, A. M. Effect of 1-methyl-2-nitrosoimidazole on intracellular thiols and calcium levels in Chinese hamster ovary cells. Biochem. Pharmacol., 42: 2153–2161, 1991.
63. Chapman, J. D., Baer, K., and Lee, J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res., 43: 1523–1528, 1983.
64. Franko, A. J., and Garrecht, B. M. Misonidazole retention by normal tissues: a distinction between label on the ring and side chain. Int. J. Radiat. Oncol. Biol. Phys., 12: 1259–1262, 1986.
65. O′Neill, P., McNeil, S. S., and Jenkins, T. C. Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131. Biochem. Pharmacol., 36: 1787–1792, 1987.
66. Zeman, E. M., and Brown, J. M. Pre- and post-irradiation radiosensitization by SR 4233. Int. J. Radiat. Oncol. Biol. Phys., 16: 967–971, 1989.
67. Wang, J., Beidermann, K. A., and Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 52: 4473–4477, 1992.
68. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67: 1163–1170, 1993.
69. Workman, P. Pharmacokinetics of hypoxic cell radiosensitizers. A review. In: L. W. Brady (ed.), Radiation Sensitizers. Their Use in the Clinical Management of Cancer, pp. 192–206. New York: Masson Publishing, 1980.